

# Influence of common preanalytical variations on the metabolic profile of serum samples in biobanks

Ophélie Fliniaux · Gwenaëlle Gaillard ·  
Antoine Lion · Dominique Cailleu ·  
François Mesnard · Fotini Betsou

Received: 12 July 2011 / Accepted: 15 September 2011 / Published online: 2 October 2011  
© Springer Science+Business Media B.V. 2011

**Abstract** A blood pre-centrifugation delay of 24 h at room temperature influenced the proton NMR spectroscopic profiles of human serum. A blood pre-centrifugation delay of 24 h at 4°C did not influence the spectroscopic profile as compared with 4 h delays at either room temperature or 4°C. Five or ten serum freeze–thaw cycles also influenced the proton NMR spectroscopic profiles. Certain common in vitro preanalytical variations occurring in biobanks may impact the metabolic profile of human serum.

**Keywords** Serum · Proton NMR · Preanalytical variation · Biobank · Biomarker · Biospecimen research · Metabolic profiling

## Abbreviations

SST Serum separation tube  
SPREC Standard preanalytical code

**Electronic supplementary material** The online version of this article (doi:10.1007/s10858-011-9574-5) contains supplementary material, which is available to authorized users.

O. Fliniaux · A. Lion · F. Mesnard (✉)  
Laboratoire de Phytotechnologie EA 3900-BioPI, University  
of Picardie Jules Verne, Amiens cedex 1, 80037 Amiens, France  
e-mail: francois.mesnard@u-picardie.fr

G. Gaillard  
Biobanque de Picardie, Avenue René Laënnec,  
80480 Salouel, France

D. Cailleu  
Plateforme Analytique, Bâtiment Serres-Transfert,  
rue de Mai/rue Dallery, 80039 Amiens cedex 1, France

F. Betsou  
Integrated Biobank of Luxembourg, 6 rue Ernest Barble,  
1210 Luxembourg, Luxembourg

TSP 3-(trimethylsilyl) 3,3,3-tetradeutero-propionic acid  
CPMG Carr-Purcell-Meiboom-Gill  
HSQC Heteronuclear single quantum coherence

## Introduction

Human biological fluid or tissue metabolomics can be successfully used in the identification of clinically relevant biomarkers by profiling spectral differences between case and control individuals (Griffin and Shockey 2004). One of the main methods used in metabolic profiling, which can be efficiently used with biological fluids and tissues, is proton NMR spectroscopy (Lindon et al. 2001; Howe and Opstad 2003; Piotta et al. 2008; Fujiwara et al. 2009). Metabolomics, through proton NMR spectroscopy, has been used efficiently in clinical and toxicological studies (Gartland et al. 1990; Holmes et al. 1998), clinical chemistry applications (Kaartinen et al. 1998), pharmacological studies (Le Moyec et al. 2005) and corresponding metabolomic data analysis procedures have been described (Lindon et al. 2005). Metabolic profiles (metabotypes) are influenced not only by disease-related processes, such as metabolic diseases, but also by the genetic background (Gavaghan et al. 2000) and by in vivo preanalytical variations including food and drug intake, exercise and stress (Walsh et al. 2006).

However, very little is known about the impact of in vitro preanalytical variations on proton NMR spectroscopy analytical endpoints (Teahan et al. 2006; Barton et al. 2008). In vitro preanalytical variations are under the direct control of biobanks. Biobanks are organized collectors and providers of biospecimens for research purposes. They collect, authenticate, preserve and offer independent access to

biological materials for a variety of technological applications. An important number of samples are often required to reach meaningful and reproducible results. Therefore researchers may need samples from different collections or from different biobank settings. These samples have almost always undergone different preanalytical treatments. Most biobanks store samples to support different research purposes and do not apply specific processing methods currently used by metabolomics laboratories, such as deproteination by ultrafiltration or acetonitrile. In this respect, it is important for biobanks to have knowledge on the suitability of a sample for specific downstream applications, in this case metabolomics. It is also important for researchers to know if they can safely use samples with different preanalytical treatments without introducing a bias linked to systematic differences in sample collection and processing. The most commonly encountered and more important pre-analytical variations can be captured through a Standard PREanalytical Code (SPREC) which has recently been described (Betsou 2010). We examined the impact of common in vitro preanalytical variations, namely pre-centrifugation conditions and freeze–thaw cycles, on serum metabolic profiles using proton NMR spectroscopy.

## Experimental

### Biological samples

Blood from 7 healthy donors (3 male and 4 female; median age 30 [24–52]) was collected in SST tubes. All donors signed an informed consent release form and the study was approved by the ethics committee and the French Biomedicine Agency (protocol no PFS09-010). Six SST tubes were collected from each donor. Of these tubes, three stood at room temperature for 4 h (more blood was collected under these conditions because they were considered as the reference), one stood at room temperature for 24 h, one was stored at 4°C for 4 h and one at 4°C for 24 h. All storage conditions were executed before centrifugation. Centrifugation was

performed at 2000×g at room temperature for 10 min. Immediately after centrifugation, serum was aliquoted in 0.2 ml aliquots and stored at –80°C in polypropylene cryotubes. The SPREC for the four different conditions were SER-SST-C-B-N-B-A, SER-SST-I-B-N-B-A, SER-SST-D-B-N-B-A and SER-SST-J-B-N-B-A respectively (Betsou 2010). Aliquots were prepared from the SER-SST-D-B-N-B-A, SER-SST-I-B-N-B-A and SER-SST-J-B-N-B-A samples. From the pooled and homogenized SER-SST-C-B-N-B-A sample, some aliquots were submitted to four freeze–thaw cycles and others were submitted to nine freeze–thaw cycles. Thawing took place at room temperature for 30 min and the samples were re-frozen at –80°C (Sukumaran et al. 2009). All samples were thawed at the moment of analysis. The same pooled and homogenized sample was used for the pre-centrifugation delay analysis. The experimental plan is shown in Table 1.

### Processing of serum samples for proton NMR

One 0.2 ml aliquot of serum was thawed at ambient temperature, diluted in 0.3 ml of D<sub>2</sub>O and homogenized by vortexing for 3 min. The pH was adjusted to 7 with a 0.1 N DCl solution in order to reduce shifts and to correspond to the pH used in the database. All final volumes were adjusted with D<sub>2</sub>O. After homogenization and centrifugation at 20160×g for 5 min, the supernatant was transferred to NMR 509-UP Norell tubes (equivalent to 535-PP Wilmad tubes) purchased from Eurisotop (91194 Saint Aubin cedex, France). A capillary containing 1 mg/ml 3-(trimethylsilyl) 3,3,3-tetradeutero-propionic acid (TSP) in D<sub>2</sub>O, as an internal reference, was introduced in the NMR 509-UP tube. TSP was used in a capillary in order to avoid TSP interference with albumin (Kriat et al. 1992; Goldsmith et al. 2009).

### Spectroscopic analysis

NMR spectra were acquired at 300 K on a Bruker AVANCE III 600 spectrometer (Magnet system 14.09 T

**Table 1** Experimental plan

No of SST tubes	3				1	1	1
	(3 serum samples pooled after centrifugation)						
Pre-centrifugation delay	4 h				4 h	24 h	24 h
Pre-centrifugation temperature	RT				4°C	RT	4°C
SPREC	SER-SST-C-B-N-B-A	SER-SST-C-B-N-B-A	SER-SST-C-B-N-B-A	SER-SST-D-B-N-B-A	SER-SST-I-B-N-B-A	SER-SST-J-B-N-B-A	
Total no of freeze–thaw cycles	1	5	10	1	1	1	

600 MHz/54 mm) equipped with a TXI 5 mm z-gradient probe. The TOPSPIN (Bruker) software was used. Shim control was performed automatically by gradient shimming and final lineshape optimization (Topshim 1D procedure). Samples were first analyzed with a classical proton sequence ( $90^\circ$  proton pulse was calibrated to  $7.36 \mu\text{s}$  at  $-1 \text{ dB}$  ( $18.34 \text{ W}$ ) then with a Carr-Purcell-Meiboom-Gill (CPMG) T2-filter sequence with an attenuation of the high molecular weight/lipid molecule effects on the spectra. For each sample, a one-dimensional proton spectrum using the CPMG pulse sequence was acquired from 128 scans containing 64 k data points, a spectral width of 6,009 Hz and relaxation delay, D1, of 2 s. The inter-pulse delay between the  $180^\circ$  pulses of the CPMG pulse train was synchronized with the sample rotation and set to  $1,400 \mu\text{s}$ . The number of loops was set to 200 so the CPMG pulse train had a total length of 283 ms. The FID was multiplied by an exponential weighing function corresponding to 0.3 Hz prior to Fourier transform. The non-zero filled obtained spectra were manually phased and baseline-corrected, calibrated to TSP at 0.00 ppm, all using XWIN NMR (version 3.3, Bruker) and finally bucketed. Bucketed spectra were separated into peaks and each peak area was calculated; each peak area corresponded to specific chemical displacements.

Furthermore, two-dimensional  $J$ -resolved NMR spectra were acquired with a 1.0 s relaxation delay using 32 scans per 128 increments that were collected into 16 K data points using spectral widths of 10,000 Hz in F2 and 78 Hz in F1. Spectra were recorded at 300 K.  $J$ -resolved spectra were tilted by  $45^\circ$  and symmetrized about F1. Coherence order selective gradient heteronuclear single quantum coherence (HSQC) spectra were recorded for a data matrix of  $256 \times 16,384$  points covering  $30,185 \times 8,013$  Hz with 92 scans for each increment. INEPT transfer delays were optimized for a heteronuclear coupling of 145 Hz and a relaxation delay of 1.5 s was applied. Data was linearly predicted in F1 to  $512 \times 16,384$  using 32 coefficients and then zero-filled to  $2,048 \times 16,384$  points prior to echo-anti echo type 2D Fourier transformation. A sine bell shaped window function, shifted by  $\pi/2$  in both dimensions, was then applied.

NMR methods show a high reproducibility through compound reference lineshape systematic control while operator variability has been shown to be negligible compared with the intrinsic variability (Sukumaran et al. 2009).


#### Data analysis

The  $^1\text{H}$ -NMR spectra were automatically reduced to ASCII files using MestReNova (v. 5.2.5, Mestrelab Research, Santiago de Compostela, Spain). Spectral intensities were scaled to TSP and reduced to integrated regions or

“buckets” of equal width (0.04 ppm) corresponding to the region of  $\delta$  9.6 to  $\delta$  0.0. The region from  $\delta$  4.85 ppm to  $\delta$  4.75 ppm was removed from the analysis due to the residual signal of water. Proton signals corresponding to TSP-d4 (at  $\delta$  0.00 ppm) were also removed. The generated ASCII file was imported into Microsoft Excel (Microsoft) for the addition of labels. Principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) were performed with the SIMCA-P software (v. 11.0, Umetrics, Umea, Sweden) (Tenenhaus et al. 1995). The scaling method for PCA and for PLS-DA was Pareto. The PLS-DA model was validated using the permutation method through 20 applications. Each signal identified by PLS-DA as discriminant was integrated using MestReNova. The resulting area was used to test the significance of the different metabolites selected by a Mann–Whitney test using the Excel software. Identification of the different metabolites was obtained via data comparison with NMR spectra of pure reference compounds and with standard metabolite chemical shift tables of the HMDB database (Wishart et al. 2009).

#### Results and discussion

A representative spectrum of human serum obtained by  $^1\text{H}$  NMR analysis is shown in Fig. 1. Several metabolites were identified (Table 2; Fig. 1). Although certain metabolites could not be identified due to the superposition of spectral peaks, most of the metabolite assignments were in agreement with previously published profiles (He et al. 2011, Psychogios et al. 2011). PCA is a non-targeted analysis and does not require identification of signals; it only




**Fig. 1** Representative one dimensional NMR  $^1\text{H}$  spectrum obtained from a serum sample, with a CPMG presat

**Table 2** Assignments of human serum metabolites (chemical shifts were referenced to the TSP at  $\delta$  0.00 ppm)

Metabolite	Chemical shift (ppm)	Multiplicity	J (Hz)
Lipid –CH <sub>3</sub>	0.80–0.91	b	
HDL	0.84	t	6.2
VLDL	0.88	t	7.3
Isoleucine	0.93	t	7.6
	1.00	d	6.9
	3.67	d	4.0
Valine	0.99	d	6.9
	1.04	d	6.9
	3.61	d	4.4
Lipid –CH <sub>2</sub>	1.16–1.37	b	
Ethanol	1.18	t	7.1
	3.66	q	7.1
Lactate	1.32	d	6.8
	4.11	q	6.9
Alanine	1.47	d	7.3
	3.78	q	7.2
Lipid –CH <sub>2</sub> CH <sub>2</sub> CO	1.53–1.62	b	
Lipid –CH <sub>2</sub> =CH	2.02–2.05	b	
Glutamate/ Glutamine	2.13	m	
Lipid –CH <sub>2</sub> –CO	2.20–2.25	b	
Acetone	2.22	s	
Glutamine	2.45	m	
Lipid = C–CH <sub>2</sub> –C=	2.65–2.85	b	
Creatine/creatinine	3.03/3.04	s	
Choline	3.20	s	
Glucose	3.24	dd	9.3, 8.3
	3.53	dd	9.9, 3.9
$\beta$ -Glucose	4.64	d	8.4
$\alpha$ -Glucose	5.23	d	3.89
Arginine	3.25	t	6.7
	3.77	t	6.2
Betaine	3.26	s	
	3.93	s	
Glycerol	3.55	dd	
	3.65	dd	
	3.77	m	
Glycine	3.55	s	
Threonine	3.58	d	4.9
Lipid =CH	5.24–5.34	b	
Tyrosine	6.89	m	
	7.19	m	
Methylhistidine	7.05	s	
	7.77	s	
Phenylalanine	7.33	d	7.0
	7.38	m	
	7.41	m	
Formic acid	8.45	s	

requires processed numerical data from spectra intensity and identifies the directions of maximum variability. We selected 3 PCs for the NMR spectra which explained 75.7% of the total variance; however the comprehensive profiles indicated that samples could not be differentiated by PCA; samples of the four different preanalytical treatments, SER-SST-C-B-N-B-A, SER-SST-D-B-N-B-A, SER-SST-I-B-N-B-A and SER-SST-J-B-N-B-A were similarly distributed. As can be seen in Fig. 2a, there was more assembly between samples from the same donor than between samples of the same preanalytical conditions. For instance, donor 1 is clearly separated from the other donors along the *x*-axis and the separations are even more distinguishable in the PLS-DA score plot (See supplementary data). Preanalytical variability was negligible compared with inter-individual variability. In this case, a supervised multivariate data analysis using covariance is required to try to associate a group of metabolites to specific preanalytical conditions. Partial least square discriminant analysis (PLS-DA) corresponds to such a supervised method. In contrast to PCA, which only uses information from the metabolomic matrix, PLS-DA also takes into account information from the matrix of the preanalytical condition types. PLS-DA showed a significant grouping of samples of the SER-SST-I-B-N-B-A preanalytical type. These samples corresponded to serum having stood at room temperature for 24 h Fig. 2b. The permutation test through 20 applications for this group and the other groups validated the PLS-DA model (Fig. 2c). Indeed, all  $Q^2$  values of permuted *Y* vectors were lower than the original ones and the regression of  $Q^2$  lines intersected the *y*-axis at below zero, indicating that the model was valid (Eriksson et al. 2001). A Mann–Whitney test was used to test the significance of the metabolites at the origin of the differential groupings. The corresponding discriminating metabolites were identified as lactate and glucose, and are visible in detail on the NMR spectra (Fig. 4a). The ratio of their corresponding areas showed an increase in lactate and a decrease in glucose when increasing the temperature and the pre-centrifugation delay. More specifically, the lactate content increased up to 2.67-fold and the glucose content decreased up to 1.67-fold between SER-SST-D-B-N-B-A and SER-SST-I-B-N-B-A (Table 3a).

Samples from the same donor and of the same SPREC (SER-SST-C-B-N-B-A), having undergone 1, 5 or 10 freeze–thaw cycles, were then compared. We selected 3 PCs for the NMR spectra which explained 79.1% of the total variance but PCA analysis did not show any significant assemblage of samples (Fig. 3a). However, PLS-DA showed a significant grouping of samples which had undergone 5 or 10 freeze–thaw cycles in comparison with only one freeze–thaw cycle (Fig. 3b). A permutation test also validated this model (Fig. 3c). The quantitative



**Fig. 2** Score plot of principal component analysis, displaying data in the transformed coordinate space (**a**) and Partial Least Square analysis (**b**) based on the pre-centrifugation delay and temperature conditions. **a** (blue), 4 h RT; **b** (light blue), 4 h 4°C; **c** (red), 24 h RT; **d** (dark blue), 24 h 4°C. S1 to S7 represent samples from donors 1–7. Plots of

permutation validation (**c**) of PLS-DA based on  $^1\text{H-NMR}$  spectra for the 24 h RT group (red) and the other groups (blue). The validation of the PLS-DA model by permutation tests through 20 applications resulted in a variance  $R^2$  of the model of 0.99 and a predictive ability  $Q^2$  of the model of 0.77

analysis of the discriminating metabolites showed that decreases in choline, glycerol, methanol, ethanol, probably proline and in an unidentified peak at 1.91 ppm were at the origin of this differential grouping after 5 or 10 freeze–thaw cycles (Table 3b; Fig. 4b). As methanol and ethanol are volatile, multiple freeze–thaw cycles could explain

their decrease through evaporation. Therefore, the common preanalytical variations linked to different pre-centrifugation conditions and/or the different numbers of freeze–thaw cycles had a visible impact on the metabolic profiles of serum samples. Targeted studies have shown no influence of such preanalytical variations on specific micromolecules

**Table 3** Metabolites at the origin of the different groupings in case of different pre-centrifugation delay and temperature conditions (A) and of different number of freeze–thaw cycles (B), including quantitative analysis and *P* value of the Mann–Whitney test


Metabolite	Ratio			<i>P</i> value		
	c/a	c/b	c/d	a, c	b, c	d, c
<b>A</b>						
Lactate	1.99	2.67	1.88	0.0017	0.0017	0.0017
Glucose	0.72	0.60	0.71	0.1417	0.0350	0.0845
Metabolite	Ratio		<i>P</i> value			
	1 day/5 day	1 day/10 day	1 day, 5 day	1 day, 10 day		
<b>B</b>						
Choline	2.75	2.88	0.0017	0.0017		
Glycerol	2.44	2.51	0.0027	0.0088		
Methanol	3.04	3.46	0.0027	0.0017		
Ethanol	2.04	1.86	0.0253	0.0350		
Unidentified peak ( $\delta$ 1.91 ppm)	1.51	1.48	0.0127	0.0350		
Proline	2.54	2.76	0.0017	0.0017		

a: 4 h RT, b: 4 h 4°C, c: 24 h RT, d: 24 h 4°C, 1 day: 1 freeze–thaw cycle, 5 day: 5 freeze–thaw cycles, 10 day: 10 freeze–thaw cycles

such as cholesterol and micronutrients (Comstock et al. 2001). However, a global metabolomic approach revealed preanalytical profiles. Previous biospecimen research, examining the effect of the pre-centrifugation time and temperature and of freeze–thaw cycles on the metabolic profiles of serum, showed some slight alterations in the NMR profiles associated with longer pre-centrifugation delays. These alterations were mainly due to an increase in lactate. The pre-centrifugation delays studied by Teahan et al. (2006) were 0.5 versus 3 h. We studied longer delays, which are practiced more often in biobanks, and, especially in large scale epidemiological biobanks. The use of sodium fluoride or other glucose preservatives is not common practice in these biobanks. Therefore, our data confirm the increase in lactate, presumably due to continued anaerobic cell metabolism, and show that this increase continues at pre-centrifugation delays between 4 and 24 h. However, lactate does not increase if blood is stored at 4°C. This is compatible with the continued anaerobic metabolism hypothesis. Prolonged storage of blood at room temperature could also be seen by a decrease in the glucose zone. Lactate production and glucose consumption may be due to prolonged contact with erythrocytes which do not have mitochondria and can only produce energy by glycolytic fermentation of glucose to lactate. Alterations in low molecular weight metabolites were found to be associated with the repeated freeze–thaw of the serum. Some of the metabolites shown to decrease after repeated freeze–

thaw, namely glycerol and choline, have been shown previously to be susceptible to post-centrifugation delays (Teahan et al. 2006). Metabolic profiles of human serum have been shown to be robust to post-centrifugation delays of up to 36 h (Barton et al. 2008). Metabolic profiles of rat plasma have also been shown to be robust to 9 month long storage at  $-80^{\circ}\text{C}$ , although, increases in glycerol and choline were observed after storage of centrifuged plasma at room temperature or 4°C (Deprez et al. 2002). Finally, our results confirm results recently published by Bernini et al. (2011) showing glucose decrease and lactate increase with pre-centrifugation delays. Metabolites such as choline and proline which were shown to be sensitive to pre-centrifugation delays (Bernini et al. 2011), were also found to be sensitive to freeze–thaw cycles in the present study.

In conclusion, inter-individual variations play a major role in NMR spectroscopy profiles while specific preanalytical variations influence specific metabolites. Although more studies, including mass spectrometry, may be conducted to confirm these findings in biological fluids of other types and in solid tissues, these data suggest that serum is sensitive to certain preanalytical variations for proton NMR spectroscopic downstream applications. Standard Operating Procedures for preanalytical handling of blood for metabolomics studies have recently been proposed (Bernini et al. 2011). Systematic recording of the blood sample collection and preparation SOP details,




**Fig. 3** Score plot of principal component analysis, displaying data in the transformed coordinate space (a) and partial least square analysis (b) based on the number of freeze–thaw cycles. 1 day (blue), baseline 1 freeze–thaw cycle; 5 day (green), 5 freeze–thaw cycles; 10 day (dark green), 10 freeze–thaw cycles. S1 to S7 represent samples from

donors 1–7. Plots of permutation validation (c) of PLS-DA based on <sup>1</sup>H-NMR spectra for the 1 freeze–thaw cycle group (blue) and the other groups (green). The validation of the PLS-DA model by permutation tests through 20 applications resulted in a variance R<sup>2</sup> of the model of 0.82 and a predictive ability Q<sup>2</sup> of the model of 0.51

according to a coding like SPREC (Betsou 2010) is recommended. This is in accordance with the previously published minimum requirements for designing and

reporting metabolic studies (Lindon et al. 2005) in order to allow preanalytical factors to be included in subsequent multivariate analyses.



**Fig. 4** NMR spectra enlargements of the zones corresponding to the discriminating metabolites' peaks for different pre-centrifugation delay and temperature conditions (**a** *blue*: 4 h RT; *light blue*: 4 h 4°C;

*red*: 24 h RT; *dark blue*: 24 h 4°C) and different number of freeze-thaw cycles (**b** *blue*: 1 freeze-thaw cycle; *green*: 5 freeze-thaw cycles; *dark green*: 10 freeze-thaw cycles)



**Acknowledgments** This work was supported by the Conseil Régional de Picardie. We are grateful to Brian de Witt and Karsten Hiller for critical reading of the manuscript.

## References

- Barton RH, Nicholson JK, Elliott P, Holmes E (2008) High-throughput  $^1\text{H}$  NMR-based metabolic analysis of human serum and urine for large-scale epidemiological studies/validation study. *Int J Epidemiol* 37 (Suppl 1):i31–i40
- Bernini P, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P (2011) Standard operating procedures for pre-analytical handling of blood and urine for metabolomics studies and biobanks. *J Biomol NMR* 49:231–243
- Betsou F, The ISBER Working Group on Biospecimen Science (2010) Standard preanalytical coding for biospecimens: defining the sample PREanalytical code (SPREC). *Cancer Epidemiol Biomarkers Prevention* 19:1004–1011
- Comstock GW, Burke AE, Norkus EP, Gordon GB, Hoffman SC, Helzlsouer KJ (2001) Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum. *Clin Chem* 47:139–142
- Deprez S, Sweatman BC, Connor SC, Haselden JN, Waterfield CJ (2002) Optimisation of collection, storage and preparation of rat plasma for  $^1\text{H}$  NMR spectroscopic analysis in toxicology studies to determine inherent variation in biochemical profiles. *J Pharm Biomed Anal* 30:1297–1310
- Eriksson L, Johansson E, Kettaneh-Wold N, Wold S (2001) Multi- and megavariable data analysis: principles and applications. Umeå, Umetrics
- Fujiwara M, Kobayashi T, Jomori T, Maruyama Y, Oka Y, Sekino H, Imai Y, Takeuchi K (2009) Pattern recognition analysis for  $^1\text{H}$  NMR spectra of plasma from hemodialysis patients. *Anal Bioanal Chem* 394:1655–1660
- Gartland KP, Sanins SM, Nicholson JK, Sweatman BC, Beddell CR, Lindon JC (1990) Pattern recognition analysis of high resolution  $^1\text{H}$  NMR spectra of urine. A nonlinear mapping approach to the classification of toxicological data. *NMR Biomed* 3:166–172
- Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK (2000) An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL/10J and Alpk:ApfCD mouse. *FEBS Lett* 484:169–174
- Goldsmith P, Raj Prasad K, Ahmad N, Fisher J (2009)  $^1\text{H}$  NMR spectroscopic study of blood serum for the assessment of liver function in liver transplant patients. *J Gastrointest Liver Dis* 18:508–517
- Griffin JL, Shockor JP (2004) Metabolic profiles of cancer cells. *Nat Rev Cancer* 4:551–564
- He Q, Ren P, Kong X, Wu Y, Wu G, Li P, Hao F, Tang H, Blachier F, Yin Y (2011) Comparison of serum metabolite compositions between obese and lean growing pigs using an NMR-based metabonomic approach. *J Nutr Biochem* (in press)
- Holmes E, Nicholls AW, Lindon JC, Ramos S, Spraul M, Neidig P, Connor SC, Connelly J, Damment SJ, Haselden J, Nicholson JK (1998) Development of a model for classification of toxin-induced lesions using  $^1\text{H}$  NMR spectroscopy of urine combined with pattern recognition. *NMR Biomed* 11:235–244
- Howe FA, Opstad KS (2003)  $^1\text{H}$  MR spectroscopy of brain tumours and masses. *NMR Biomed* 16:123–131
- Kaartinen J, Hiltunen Y, Kovanen PT, Ala-Korpela M (1998) Application of self-organizing maps for the detection and classification of human blood plasma lipoprotein lipid profiles on the basis of  $^1\text{H}$  NMR spectroscopy data. *NMR Biomed* 11:168–176
- Kriat M, Confort-Gouny S, Vion-Dury J, Sciaky M, Viout P, Cozzone PJ (1992) Quantitation of metabolites in human blood serum by proton magnetic resonance spectroscopy. A comparative study of the use of formate and tSP as concentration standards. *NMR Biomed* 5:179–184
- Le Moyec L, Valensi P, Charniot JC, Hantz E, Albertini JP (2005) Serum  $^1\text{H}$ -nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients. *NMR Biomed* 18:421–429
- Lindon JC, Holmes E, Nicholson JK (2001) Pattern recognition methods and applications in biomedical magnetic resonance. *Prog Nucl Magn Reson Spectrosc* 39:1–40
- Lindon JC, Nicholson JK, Holmes E, Keun HC, Craig A, Pearce JTM, Bruce SJ, Hardy N, Sansone SA, Antti H, Jonsson P, Daykin C, Navarange M, Beger RD, Verheij ER, Amberg A, Baunggaard D, Cantor GH, Lehman-McKeeman L, Earll M, Wold S, Johansson E, Haselden JN, Kramer K, Thomas C, Lindberg J, Schuppe-Koistinen I, Wilson ID, Reily Schaefer H, Spraul M (2005) Summary recommendations for standardization and reporting of metabolic analyses. *Nat Biotechnol* 23:833–838
- Piotto M, Moussallieh FM, Dillmann B, Imperiale A, Neuville A, Brigand C, Bellocq JP, Elbayed K, Namer JJ (2008) Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning  $^1\text{H}$  magnetic resonance spectroscopy. *Metabolomics* 5:292–301
- Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS (2011) The human serum metabolome. *PLoS One* 6(2):e16957
- Sukumaran DK, Garcia E, Hua J, Tabaczynski W, Odunsi K, Andrews C, Szyperski T (2009) Standard operating procedure for metabonomic studies of blood serum and plasma samples using a  $^1\text{H}$ -NMR micro-flow probe. *Magn Reson Chem* 47:S81–S85
- Teahan O, Gamble S, Holmes E, Waxman J, Nicholson JK, Bevan C, Keun HC (2006) Impact of analytical bias in metabonomic studies of human blood serum and plasma. *Anal Chem* 78:4307–4318
- Tenenhaus M, Gauchi JP, Menardo C (1995) Regression PLS et applications. *Revue Statistique Appliquée XLIII(1):7–63*
- Walsh MC, Brennan L, Malthouse JPG, Roche HM, Gibney MJ (2006) Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. *Am J Clin Nutr* 84:531–539
- Wishart DS, Knox C, Guo AC et al. (2009) HMDB: a knowledgebase for the human metabolome. *Nucleic Acids Res* 37(Database issue):D603–D610